RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
YANTAI, China, March 11, 2024 /PRNewswire/ — RemeGen Co. Ltd.(“RemeGen” or “the Company”) (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an i… อ่านเพิ่ม